STRUCTURED ABSTRACT
INTRODUCTION A recently developed mild behavioral impairment (MBI) diagnostic framework standardizes the early characterization of neuropsychiatric symptoms in older adults. However, the links between MBI, brain function, and Alzheimer’s disease (AD) biomarkers are unclear.
METHODS Using data from 128 participants with diagnosis of amnestic mild cognitive impairment and mild dementia – Alzheimer’s type, we test a novel model assessing direct relationships between AD biomarker status and MBI symptoms, as well as mediated effects through segregation of the salience and default-mode networks.
RESULTS We identified a mediated effect of tau positivity on MBI through functional segregation of the salience network from the other high-level, association networks. There were no direct effects of AD biomarkers status on MBI.
DISCUSSION Our findings suggest an indirect role of tau pathology in MBI through brain network dysfunction and emphasize the role of the salience network in mediating relationships between neuropathological changes and behavioral manifestations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the NIH/NIA via R01AG058724 (to B.M.H.) and R35AG072262 (to B.M.H. for effort and infrastructure).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Michigan Institutional Research Board approved this study. All participants or their legally authorized representative provided written informed consent (and assent as appropriate).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data sets analyzed for this study may be available upon reasonable request to the corresponding author, pending approval from participants and adherence with the NIH and local approval mechanisms.
